Researchers from University of Georgia in the US also noted that there was a big spike in 2013, the year in which Jolie revealed she carries a mutation.
A breast cancer (BRCA) gene test is a blood test to check for mutations in genes called BRCA1 and BRCA2. This test predict the risk of getting breast cancer and ovarian cancer.
"Appropriate use of BRCA testing would lead to reduction in avoidable cancer mortalities and morbidities," Chen said.
Women with hereditary BRCA gene mutations have a 45 to 65 per cent risk of developing breast cancer before age 70, compared to seven per cent in the general population, according to the US National Cancer Institute.
The study, published in the journal Genetics in Medicine analysed testing rates, payment to the provider, and out-of- pocket costs for patients from 2003 to 2014, and compared findings to reported revenue from Myriad Genetics, the only provider of the test until 2013.
That same year Hollywood actress Angelina Jolie published an op-ed in The New York Times promoting BRCA gene testing and the Supreme Court struck down the patent on BRCA gene testing, researchers said.
"This could provide insights on the impact of the policy changes and the media coverage of celebrity endorsement," said Chen.
Though it may be tempting to connect the whirlwind of media coverage surrounding Jolie's decision to have a double mastectomy following a positive BRCA test, the available data cannot point to which event had a greater impact, researchers said.
"In a companion study, we did examine whether women had follow-up surgical procedures and found an urban and rural disparity in the follow-up rates," said Chen.
"Women residing in urban areas consistently had a higher rates of follow-up surgical procedures than those in rural areas, though the gap is narrowing," Chen added
As genetic testing becomes more accessible, potential for individuals to make more informed decisions about their health, researchers said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
